• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A new era for small molecule screening: from new targets, such as JAK2 V617F, to complex cellular screens.小分子筛选的新时代:从新靶点,如JAK2 V617F,到复杂的细胞筛选。
J Cell Mol Med. 2009 Feb;13(2):212-214. doi: 10.1111/j.1582-4934.2008.00666.x.
2
Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.JAK2 V617F 导致血小板生成素受体下调:病理性 JAK2 信号和蛋白酶体抑制剂可恢复受体水平。
Blood. 2012 May 17;119(20):4625-35. doi: 10.1182/blood-2011-08-372524. Epub 2012 Feb 29.
3
MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.JAK2 突变阴性的骨髓增殖性疾病患者的 MPL 突变谱
Diagn Mol Pathol. 2011 Mar;20(1):34-9. doi: 10.1097/PDM.0b013e3181ecd261.
4
JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.JAK2 GGCC 单倍型在 MPL 突变骨髓增殖性肿瘤中的作用。
Am J Hematol. 2012 Jul;87(7):746-7. doi: 10.1002/ajh.23229. Epub 2012 May 6.
5
Low V617F Allele Burden in Ph-Negative Chronic Myeloproliferative Neoplasms Is Associated with Additional or Gene Mutations.Ph 阴性慢性骨髓增殖性肿瘤中低 V617F 等位基因负担与其他 或 基因突变相关。
Genes (Basel). 2021 Apr 12;12(4):559. doi: 10.3390/genes12040559.
6
Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden.JAK2(V617F)等位基因负担较低的患者中,JAK2外显子12或MPL外显子10共突变的频率增加。
Leuk Lymphoma. 2016;57(6):1429-35. doi: 10.3109/10428194.2015.1091932. Epub 2015 Dec 23.
7
Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway.富勒烯衍生物通过抑制 c-Jun N-末端激酶通路预防 JAK2 V617F 突变体诱导的细胞转化。
Cell Signal. 2012 Nov;24(11):2024-34. doi: 10.1016/j.cellsig.2012.06.014. Epub 2012 Jun 30.
8
JAK2, the JAK2 V617F mutant and cytokine receptors.JAK2、JAK2 V617F突变体和细胞因子受体。
Pathol Biol (Paris). 2007 Mar;55(2):88-91. doi: 10.1016/j.patbio.2006.06.003. Epub 2006 Aug 14.
9
Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling.JAK2 V617 突变体抑制策略对细胞因子受体信号的差异影响。
J Allergy Clin Immunol. 2019 Jul;144(1):224-235. doi: 10.1016/j.jaci.2018.12.1023. Epub 2019 Jan 29.
10
Comparison of two homogeneous cell-based kinase assays for JAK2 V617F: SureFire pSTAT5 and GeneBLAzer fluorescence resonance energy transfer assays.两种用于检测JAK2 V617F的基于细胞的均相激酶分析方法的比较:SureFire pSTAT5和GeneBLAzer荧光共振能量转移分析方法。
Assay Drug Dev Technol. 2012 Apr;10(2):212-7. doi: 10.1089/adt.2011.0399. Epub 2011 Dec 1.

引用本文的文献

1
Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies.急性淋巴细胞白血病的改变:卓越精准医学策略的分子见解
Front Cell Dev Biol. 2022 Jul 12;10:942053. doi: 10.3389/fcell.2022.942053. eCollection 2022.
2
Therapeutic potential of JAK2 inhibitors.JAK2 抑制剂的治疗潜力。
Hematology Am Soc Hematol Educ Program. 2009:636-42. doi: 10.1182/asheducation-2009.1.636.

本文引用的文献

1
Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2.JAK2抑制剂AZ960对人JAK2 V617F细胞系SET-2中Pim/BAD/BCL-xL存活信号通路的影响。
J Biol Chem. 2008 Nov 21;283(47):32334-43. doi: 10.1074/jbc.M803813200. Epub 2008 Sep 4.
2
JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.病理学中的JAKs:Janus激酶在血液系统恶性肿瘤和免疫缺陷中的作用
Semin Cell Dev Biol. 2008 Aug;19(4):385-93. doi: 10.1016/j.semcdb.2008.07.002. Epub 2008 Jul 17.
3
SIRT1 confers protection against UVB- and H2O2-induced cell death via modulation of p53 and JNK in cultured skin keratinocytes.SIRT1 通过调节培养皮肤角质细胞中的 p53 和 JNK,对 UVB 和 H2O2 诱导的细胞死亡起保护作用。
J Cell Mol Med. 2009 Sep;13(9B):3632-43. doi: 10.1111/j.1582-4934.2008.00453.x. Epub 2008 Aug 4.
4
Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.急性白血病和实体癌中JAK1和JAK3的体细胞突变。
Clin Cancer Res. 2008 Jun 15;14(12):3716-21. doi: 10.1158/1078-0432.CCR-07-4839.
5
Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization.血小板衍生生长因子受体胞外域膜近端区域之间的接触是受体激活所必需的,但不是受体二聚化所必需的。
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7681-6. doi: 10.1073/pnas.0802896105. Epub 2008 May 27.
6
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.一种小分子p53激活剂的发现、体内活性及作用机制
Cancer Cell. 2008 May;13(5):454-63. doi: 10.1016/j.ccr.2008.03.004.
7
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.成人急性淋巴细胞白血病中的体细胞获得性JAK1突变
J Exp Med. 2008 Apr 14;205(4):751-8. doi: 10.1084/jem.20072182. Epub 2008 Mar 24.
8
Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F.细胞因子受体介导的二聚化对于JAK2V617F的组成性激活是必需的。
J Biol Chem. 2008 Feb 29;283(9):5258-66. doi: 10.1074/jbc.M707125200. Epub 2007 Dec 23.
9
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).组蛋白去乙酰化酶抑制剂ITF2357可选择性地作用于携带JAK2(V617F)突变的细胞。
Leukemia. 2008 Apr;22(4):740-7. doi: 10.1038/sj.leu.2405049. Epub 2007 Dec 13.
10
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials.JAK2抑制剂治疗骨髓增殖性疾病:原理、临床前研究及正在进行的临床试验。
Leukemia. 2008 Jan;22(1):23-30. doi: 10.1038/sj.leu.2404948. Epub 2007 Sep 20.

小分子筛选的新时代:从新靶点,如JAK2 V617F,到复杂的细胞筛选。

A new era for small molecule screening: from new targets, such as JAK2 V617F, to complex cellular screens.

作者信息

Constantinescu Stefan N

出版信息

J Cell Mol Med. 2009 Feb;13(2):212-214. doi: 10.1111/j.1582-4934.2008.00666.x.

DOI:10.1111/j.1582-4934.2008.00666.x
PMID:19183237
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3823349/
Abstract

Traditionally reserved to research and development in pharmaceutical companies, screening of small molecule libraries is rapidly becoming an approach undertaken by academic laboratories. Novel cellular assays, sensitive systems to probe function, emerging new molecular targets are just some of the reasons explaining this shift. Targets of small molecules identified in cellular screens begin to be amenable to identification by elegant genetic approaches, such as probing toxicity of candidate small molecules on libraries of genetically modified yeast strains. Several new targets, such as JAK2 V617F, an activated JAK2 (Janus Kinase 2) mutant genetically associated with the majority of human myeloproliferative neoplasms, are being actively pursued. In this Review Series, we will learn how libraries of small molecules are harnessed to identify novel molecules, that alone or in combination, have the ability to alter cell fate, cell signalling, gene expression or response to extracellular cues.

摘要

小分子文库筛选传统上是制药公司研发部门的专属工作,如今正迅速成为学术实验室采用的一种方法。新型细胞分析、用于探究功能的灵敏系统以及新出现的分子靶点,只是解释这一转变的部分原因。在细胞筛选中鉴定出的小分子靶点开始可以通过精妙的遗传学方法来识别,比如探究候选小分子对基因改造酵母菌株文库的毒性。几个新靶点,如JAK2 V617F(一种与大多数人类骨髓增殖性肿瘤存在遗传关联的活化JAK2(Janus激酶2)突变体),正受到积极研究。在本综述系列中,我们将了解小分子文库如何被用于鉴定单独或联合使用时能够改变细胞命运、细胞信号传导、基因表达或对细胞外信号反应的新型分子。